Emanuele Vita

Rome, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 49 publications

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

From Clinical Trials to Real-World Practice: Surgical Feasibility and Postoperative Outcomes After Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC in a Single-Center Experience.

From Clinical Trials to Real-World Practice: Surgical Feasibility and Postoperative Outcomes After Neoadjuvant Chemoimmunotherapy for Locally Advanced NSCLC in a Single-Center Experience.

Journal: Cancers

Published: May 08, 2026

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Journal: Tumori

Published: May 04, 2026

Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.

Design-Outcome Concordance in Targeted-Therapy trials in Non-Small cell lung cancer: a Meta-Research study.

Journal: Journal of the National Cancer Institute

Published: April 09, 2026

Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review.

Primary adrenal insufficiency induced by immune checkpoint inhibitors (ICIs): a case series and systematic literature review.

Journal: Reviews in endocrine & metabolic disorders

Published: February 11, 2026

Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice.

Endocrine toxicities in immune checkpoint inhibitors and tyrosine kinase inhibitors combined treatment: from clinical trials to real-life practice.

Journal: Endocrine

Published: December 16, 2025

Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.

Consolidation thoracic radiotherapy after chemoimmunotherapy in ES-SCLC: A multicentric retrospective analysis.

Journal: European journal of cancer (Oxford, England : 1990)

Published: May 08, 2025

Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib.

Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib.

Journal: ESMO open

Published: April 16, 2025

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.

PI3K/mTORC2-RICTOR axis in early squamous non-small-cell lung cancer: genomics, molecular expression, and clinical relevance.

Journal: Therapeutic advances in medical oncology

Published: April 02, 2025

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.

Correlation between irAEs and survival outcomes in patients with ES-SCLC treated with first-line chemoimmunotherapy.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 25, 2025

COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.

COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.

Journal: Vaccines

Published: December 30, 2024

Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.

Overcoming amplification-mediated resistance to sotorasib by dose re-escalation in KRAS G12C mutant NSCLC: a case report.

Journal: The oncologist

Published: December 19, 2024

Showing 1-12 of 49

Last Updated: 09/26/2026